Literature DB >> 22342773

Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity.

Tatum V Tarin1, Nicholas E Power, Behfar Ehdaie, John P Sfakianos, Jonathan L Silberstein, Caroline J Savage, Daniel Sjoberg, Guido Dalbagni, Bernard H Bochner.   

Abstract

BACKGROUND: The extent of lymphadenectomy needed to optimize oncologic outcomes after radical cystectomy (RC) for patients with regionally advanced bladder cancer (BCa) is unclear.
OBJECTIVE: Evaluate the effect of the location of lymph node metastasis on recurrence-free survival (RFS) and cancer-specific survival (CSS) for patients undergoing RC with a mapping pelvic lymph node dissection (PLND). DESIGN, SETTING, AND PARTICIPANTS: A study of 591 patients undergoing RC with mapping PLND was completed between 2000 and 2010. Median follow-up was 30 mo. INTERVENTION: RC with mapping PLND. MEASUREMENTS: We evaluated the impact of lymph node involvement by location on disease outcomes using the 2010 TNM staging system. Survival estimates were described using Kaplan-Meier methods. Gender, age, pathologic stage, histology, number of positive nodes, location of positive nodes, node density, use of perioperative chemotherapy, and grade were evaluated as predictors of RFS and CSS using multivariate Cox proportional hazard regression. RESULTS AND LIMITATIONS: Overall, 114 patients (19%) had lymph node involvement, and 42 patients (7%) had pN3 disease. On multivariate analysis, the number of positive lymph nodes (one or two or more) was significantly associated with increased risk of cancer-specific death (hazard ratio [HR]: 1.9 [95% confidence interval (CI), 1.04-3.46], p=0.036; versus HR: 4.3 [95% CI, 2.25-8.34], p<0.0005). Positive lymph node location was not an independent predictor of RFS or CSS. Five-year RFS for pN3 patients undergoing RC with PLND was 25% (95% CI, 10-42). This finding was not statistically different from our pN1 and pN2 patients (38% [95% CI, 22-54] and 35% [95% CI, 11-60], respectively). This study is limited by the lack of prospective randomization and a control group.
CONCLUSIONS: The outcome for patients with involved common iliac lymph nodes was similar to the outcome for patients with primary nodal basin disease. These data support inclusion of the common iliac lymph nodes (pN3) in the nodal staging system for BCa. Lymph node location was not an independent predictor of outcome, whereas the number of positive lymph nodes was an independent predictor of worse oncologic outcome (pN1, pN2). Further refinements of the TNM system to provide improved prognostication are warranted.
Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22342773      PMCID: PMC4035150          DOI: 10.1016/j.eururo.2012.01.049

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  17 in total

1.  Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens.

Authors:  B H Bochner; H W Herr; V E Reuter
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

2.  Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer.

Authors:  Bernard H Bochner; Michael W Kattan; Kinjal C Vora
Journal:  J Clin Oncol       Date:  2006-07-24       Impact factor: 44.544

3.  Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study.

Authors:  J Leissner; M A Ghoneim; H Abol-Enein; J W Thüroff; L Franzaring; M Fisch; H Schulze; G Managadze; E P Allhoff; M A el-Baz; H Kastendieck; P Buhtz; S Kropf; R Hohenfellner; H K Wolf
Journal:  J Urol       Date:  2004-01       Impact factor: 7.450

4.  Surgical factors influence bladder cancer outcomes: a cooperative group report.

Authors:  Harry W Herr; James R Faulkner; H Barton Grossman; Ronald B Natale; Ralph deVere White; Michael F Sarosdy; E David Crawford
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

5.  The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer.

Authors:  A R Feinstein; D M Sosin; C K Wells
Journal:  N Engl J Med       Date:  1985-06-20       Impact factor: 91.245

6.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Authors:  H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

7.  Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping.

Authors:  Bernard H Bochner; Daniel Cho; Harry W Herr; Machele Donat; Michael W Kattan; Guido Dalbagni
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

8.  Outcome after radical cystectomy with limited or extended pelvic lymph node dissection.

Authors:  Nivedita Bhatta Dhar; Eric A Klein; Alwyn M Reuther; George N Thalmann; Stephan Madersbacher; Urs E Studer
Journal:  J Urol       Date:  2008-01-25       Impact factor: 7.450

9.  Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only.

Authors:  Kenneth Steven; Asger L Poulsen
Journal:  J Urol       Date:  2007-08-14       Impact factor: 7.450

10.  Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall.

Authors:  A L Poulsen; T Horn; K Steven
Journal:  J Urol       Date:  1998-12       Impact factor: 7.450

View more
  32 in total

1.  The impact of female gender on bladder cancer-specific death risk after radical cystectomy: a meta-analysis of 27,912 patients.

Authors:  Shenghua Liu; Tian Yang; Rong Na; Mengbo Hu; Limin Zhang; You Fu; Haowen Jiang; Qiang Ding
Journal:  Int Urol Nephrol       Date:  2015-04-19       Impact factor: 2.370

Review 2.  Extent of pelvic lymph node dissection during radical cystectomy: is bigger better?

Authors:  Debasish Sundi; Robert S Svatek; Matthew E Nielsen; Mark P Schoenberg; Trinity J Bivalacqua
Journal:  Rev Urol       Date:  2014

Review 3.  The survival benefit of lymph node dissection at the time of removal of kidney, prostate and urothelial carcinomas: what is the evidence?

Authors:  Karim Bensalah; Morgan Roupret; Evanguelos Xylinas; Shahrokh Shariat
Journal:  World J Urol       Date:  2013-04-16       Impact factor: 4.226

4.  Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion.

Authors:  Michael J Metcalfe; James E Ferguson; Roger Li; Lianchun Xiao; Charles C Guo; Bogdan A Czerniak; Arlene Siefker-Radtke; Shanna M Pretzsch; Neema Navai; David J McConkey; Ashish M Kamat; Mathew Campbell; Colin Dinney
Journal:  Eur Urol Focus       Date:  2017-07-13

5.  Is there evidence for a close connection between side of intravesical tumor location and ipsilateral lymphatic spread in lymph node-positive bladder cancer patients at radical cystectomy? Results of the PROMETRICS 2011 database.

Authors:  M May; C Protzel; M W Vetterlein; M Gierth; J Noldus; A Karl; T Grimm; B Wullich; M O Grimm; P Nuhn; P J Bastian; J Roigas; B Hadaschik; C Gilfrich; M Burger; M Fisch; S Brookman-May; A Aziz; O W Hakenberg
Journal:  Int Urol Nephrol       Date:  2016-11-28       Impact factor: 2.370

6.  The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review.

Authors:  Mohammad Abufaraj; Guido Dalbagni; Siamak Daneshmand; Simon Horenblas; Ashish M Kamat; Ryu Kanzaki; Alexandre R Zlotta; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2017-11-07       Impact factor: 20.096

7.  Development, validation and clinical application of Pelvic Lymphadenectomy Assessment and Completion Evaluation: intraoperative assessment of lymph node dissection after robot-assisted radical cystectomy for bladder cancer.

Authors:  Ahmed A Hussein; Nobuyuki Hinata; Shiva Dibaj; Paul R May; Justen D Kozlowski; Hassan Abol-Enein; Ronney Abaza; Daniel Eun; Mohamed S Khan; James L Mohler; Piyush Agarwal; Kamal Pohar; Richard Sarle; Ronald Boris; Sridhar S Mane; Alan Hutson; Khurshid A Guru
Journal:  BJU Int       Date:  2017-01-18       Impact factor: 5.588

Review 8.  Lymph node dissection during radical cystectomy for bladder cancer treatment: considerations on relevance and extent.

Authors:  Lars Weisbach; Roland Dahlem; Giuseppe Simone; Jens Hansen; Armin Soave; Oliver Engel; Felix K Chun; Shahrokh F Shariat; Margit Fisch; Michael Rink
Journal:  Int Urol Nephrol       Date:  2013-07-25       Impact factor: 2.370

9.  Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.

Authors:  Timur Mitin; Daniel Hunt; William U Shipley; Donald S Kaufman; Robert Uzzo; Chin-Lee Wu; Mark K Buyyounouski; Howard Sandler; Anthony L Zietman
Journal:  Lancet Oncol       Date:  2013-07-01       Impact factor: 41.316

10.  Pathological characteristics and prognostic indicators of different histopathological types of urinary bladder cancer following radical cystectomy in a large single-center Egyptian cohort.

Authors:  Jeremy W Martin; Simone L Vernez; Yair Lotan; Ahmed Abdelhalim; Rahul Dutta; Ahmed Shokeir; Hassan Abol-Enein; Ahmed Mosbah; Mohamed Ghoneim; Ramy F Youssef
Journal:  World J Urol       Date:  2018-05-14       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.